Research and development

In order for patients to feel comfortable being treated with cell medicine, we have worked on a variety of activities for research and development. Such activities include the publication of clinical research and experience for evidence enforcement, the acquisition of new potent cancer antigens, the improvement of cultivation efficiency and the quality of dendritic cells, and the research and development of new immunotherapies.

Research and development of regenerative medicine and cell medicine, including dendritic cell vaccine therapy

  1. ① Clinical research of dendritic cell vaccine therapy

    As for the collaborative clinical research conducted with research institutions including universities on dendritic cell vaccine therapy, we work on supports such as construction of systems to analyze clinical data and the documentation of the research to enforce the evidence.

    Efforts toward continuous improvement
  2. ② Research and development of new cancer antigens

    Cancer antigens are one of the most important substances needed in dendritic cell vaccine therapies. Increased choices of new cancer antigens may lead to more patients receiving the treatment and possibly enhanced effects of dendritic cell vaccine therapies.

    Cancer antigens to which tella, Inc. holds exclusive rights for use.

    ・WT1 peptide
    ・MAGE-A4 peptide
    ・Survivin peptide
    ・hUVEC protein

    tella's "dendritic cell vaccine therapy" for cancer
  3. ③ Research and development on new immunotherapy

    With Nagasaki University, we launched clinical studies of ZNK®ell immunotherapy as a new immunotherapy. Combining this therapy with dendritic cell vaccine therapy may exert more benefits in cancer treatment. In collaboration with Kyushu University, we have applied for a patent on the technology of cultivating ZNK®cells with an approximately 10-fold higher capability of killing cancer cells than in general NK cell activities.

    What is natural killer cell therapy?

    NK cell therapy is a theraputic taking advantage of NK cells, which are effective in killing virally-infected or cancer cells. In clinical studies on NK cell therapy, traditionally conducted in Europe and the United States, NK cells were not adequately amplified or activated outside the body and adequate antitumor effects were not obtained.
    tella and Kyushu University have resolved the traditional issues and applied for a patent on the new technology of cultivating new NK cells (ZNK cells) that are highly effective in killing cancer cells.

  4. ④ Research and development of cell processing devices

    We entered an agreement with Asahi Kasei Corporation on collaborative research on cell processing device research and development. We promote collaborative research and development for achieving the practical use of cell processing devices in cancer treatment for the stable and efficient cultivation of high-quality cells.

  5. ⑤ Research on pharmaceutical products including dendritic cell vaccine therapy

    We work on activities to promote the development of cellular pharmaceutical products derived from dendritic cell vaccines.
    We signed an agreement with Kyushu University on collaborative research, and launched feasibility studies for manufacturing cellular pharmaceutical products derived from dendritic cell vaccines, in accordance with the GMP for investigational drugs. Through this collaborative research, we promote appropriate documentation styles, manufacturing systems and field investigations on all manufacturing procedures according to the GMP for investigational drugs, which are necessary for the development of cellular pharmaceutical products.

TopPage